Press Releases

 
Press Releases
  Date Title and Summary View
Oct 6, 2017
CRANBURY, N.J., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the appointment of Michael C. Diem, MD as Senior Vice President of Business and Corporate Development. He will be responsible for leading all business and corporate development activities. Dr. Diem will be a key member of the Amicus senior leadersh...
PDF
Oct 4, 2017
Mean Six-Minute Walk Distance Improved in ERT-Naive Patients (+42 Meters at 6 Months, +75 Meters at 9 Months) and ERT-Switch Patients (+35 Meters at 6 Months, +37 Meters at 9 Months) Persistent & Durable Reductions in Key Disease Biomarkers Pulmonary Function Generally Improved or Remained Stable at 6 and 9 Months Very Low Number (...
PDF
Sep 21, 2017
CRANBURY, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the U.S. FDA has granted orphan drug designation to ATB200/AT2221 for the treatment of Pompe disease, an inherited lysosomal storage disorder caused by deficiency of an enzyme called acid alpha-glucosidase (GAA). This novel treatment paradigm cons...
PDF
Sep 20, 2017
CRANBURY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Wednesday, September 27, 2017 at 1:00 p.m...
PDF
Sep 19, 2017
CRANBURY, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the oral precision medicine migalastat for the treatment of patients with Fabry disease with amenable mutations. The FDA's Fast Track program is designed to expedite...
PDF
Sep 14, 2017
CRANBURY, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that Health Canada has approved the oral precision medicine Galafold for long-term treatment of adults with a confirmed diagnosis of Fabry disease [deficiency of alpha-galactosidase (alpha-Gal A)] and who have an alpha-Gal A mutation determined to be am...
PDF
Sep 13, 2017
Study Did Not Meet Primary Endpoints Conference Call and Webcast Today at 8:30am ET CRANBURY, N.J., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) reported that top-line data from the randomized, double-blind, placebo-controlled Phase 3 clinical study (ESSENCE, SD-005) to assess the efficacy and safety of the nov...
PDF
Aug 25, 2017
CRANBURY, N.J., Aug. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that 6 posters highlighting its Fabry program will be included in the 13th International Congress of Inborn Errors of Metabolism to be held September 5-8, 2017 in Rio de Janeiro, Brazil. Poster Sessions: Wednesday, September 6, 2017 from 5:30...
PDF
Aug 15, 2017
First Amicus Medicine and First Oral Precision Medicine for Fabry Disease in Australia Broad Label for Fabry Patients with an Amenable Genetic Mutation CRANBURY, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Australian Therapeutic Goods Administration (TGA) has approved the oral precision medi...
PDF
Aug 7, 2017
179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 - On Target to Reach 300 Patients by Year-End 2017 Migalastat NDA Submission Targeted for 4Q17 Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17 CRANBURY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a g...
PDF
Page:
1
... NextLast